Fig. 1.

Absolute numbers of a CD4⁺, b CD8⁺, c NK and d NKT cells at baseline, during and after therapy. Lenalidomide was administered on weeks 1–16 and alemtuzumab weeks 5–16. Median number of cells/µL at each time point is depicted under each figure. * p < 0.05, ** p < 0.01, *** p < 0.001